Live Breaking News & Updates on Antony Blanc|Page 5

Stay updated with breaking news from Antony blanc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic


Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
April 19, 2021 GMT
Review process started with submission of first CVnCoV data package
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 19, 2021 / The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland. The application for authorization was submitted to Swissmedic, the country’s authority responsible for the authorization and supervision of therapeutic products including vaccines. ....

United States , Antony Blanc , Sarah Fakih , Exchange Commission , European Union , European Medicines Agency , European Commission , Curevac Swiss , Chief Business Officer , Chief Commercial Officer , Latin America , Lipid Nanoparticles , New York Nasdaq , Vice President , Vice President Investor , Public Health , Government Business And Finance , Products And Services , Government Regulations , Coronavirus Pandemic , Product Testing , Government Contracts , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic ,

CureVac (CVAC) Q4 2020 Earnings Call Transcript


Sarah Fakih
Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih. I m the vice president of investor relations at CureVac.
Please let me introduce today s speakers. On the call with me are Franz Haas, the chief executive officer of CureVac; Pierre Kemula, our chief financial officer; and Ulrike Gnad-Vogt, our interim chief development officer. Mariola Fotin-Mleczek, the CureVac chief technology officer will be available for the Q&A session after the presentation. Please note that this call is being webcast live and will be archived on the events and presentations section under investor relations on our website. ....

United States , Baden Wüberg , South Africa , South African , Seamus Fernandez Guggenheim , America Merrill Lynch , Ulrike Gnad Vogt , Mariola Fotin Mleczek , Serra Goudarzi Jefferies , Seamus Fernandez , Eli Lilly , Pierre Kemula , Zhiqiang Shu Berenberg , Eun Yang , Antony Blanc , Sarah Fakih , Shu Zhiqiang , Franz Haas , Geoff Meacham , Aspen Mori Bank , German Federal Ministry Of Education , European Commission , Exchange Commission , Harvard University , European Union , European Medicines Agency ,

Investegate |CureVac Announcements | CureVac: CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020


DGAP-News: CureVac
/ Key word(s): Quarter Results/Annual Results
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
15.04.2021 / 13:30
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
-
COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission
- Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021
- Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60 ....

United States , United Kingdom , South Africa , South African , Rentschler Biopharma , Antony Blanc , Wacker Chemie , Sarah Fakih , Franz Werner Haas , Eli Lilly , Pierre Kemula , Contract Development , Vaccine Program , Coalition For Epidemic Preparedness Innovations , Manufacturing Organization , Celonic Group , Vaccines Task , European Union , Program Products , European Investment Bank , Society For Immunotherapy Of Cancer , German Federal Ministry Of Education , European Commission , Exchange Commission , European Medicines Agency , Partnership Agreements ,